BMY Stock Analysis: Bristol-Myers Squibb | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 118.706m USD | 12M Return: 27.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 682M
EPS Trend: 13.4%
Qual. Beats: 0
Rev. Trend: 92.2%
Qual. Beats: 10
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bristol-Myers Squibb Company (NYSE: BMY) is a U.S.-based global biopharmaceutical company headquartered in Princeton, New Jersey. Founded in 1887, the company discovers, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products worldwide, operating within the Health Care sector and the Pharmaceuticals sub-industry.
The company maintains a diversified portfolio spanning oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas. Its oncology franchise includes key drugs such as Opdivo (an anti-PD-1 immunotherapy), Yervoy, Opdualag, Breyanzi, Abecma, Krazati, Augtyro, and Abraxane. Immunology offerings include Orencia, Zeposia, Sotyktu, and Cobenfy, while its cardiovascular and hematology products include Eliquis, Camzyos, Reblozyl, Revlimid, Pomalyst/Imnovid, and Sprycel.
Like most large-cap pharmaceutical companies, BMY relies on a wholesale and specialty distribution model, selling its products through wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. This distribution structure reflects the sectors typical reliance on third-party intermediaries to reach both patients and providers across multiple regions.
The company maintains strategic collaborations with smaller biotechnology firms to expand its pipeline, including a partnership with Arcus Biosciences focused on developing novel treatments for kidney cancer. Such licensing and collaboration agreements are common within the biopharmaceutical industry, allowing large-cap companies to access innovation from smaller research-focused partners without bearing the full cost of early-stage drug discovery.
- Eliquis Medicare price negotiations and patent cliff pressure 2026 revenue
- Cobenfy schizophrenia launch drives neuroscience segment revenue growth
- High acquisition debt weighs on margins and capital returns
| Net Income: 7.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -0.39 > 1.0 |
| NWC/Revenue: 16.60% < 20% (prev 14.09%; Δ 2.51% < -1%) |
| CFO/TA 0.15 > 3% & CFO 13.3b > Net Income 7.28b |
| Net Debt (35.9b) to EBITDA (13.7b): 2.61 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.32% < -2% |
| Gross Margin: 68.75% > 18% (prev 59.16%; Δ 9.59% > 0.5%) |
| Asset Turnover: 54.20% > 50% (prev 51.54%; Δ 2.66% > 0%) |
| Interest Coverage Ratio: 7.33 > 6 (EBIT TTM 10.5b / Interest Expense TTM 1.43b) |
| A: 0.09 (Total Current Assets 27.2b - Total Current Liabilities 19.2b) / Total Assets 86.5b |
| B: 0.21 (Retained Earnings 18.3b / Total Assets 86.5b) |
| C: 0.12 (EBIT TTM 10.5b / Avg Total Assets 89.5b) |
| D: 0.30 (Book Value of Equity 20.1b / Total Liabilities 66.4b) |
| Altman-Z'' = 2.40 = A |
| DSRI: 0.81 (Receivables 12.1b/14.6b, Revenue 48.5b/47.6b) |
| GMI: 0.86 (GM 59.16% / 68.75%) |
| AQI: 1.01 (AQ_t 0.58 / AQ_t-1 0.58) |
| SGI: 1.02 (Revenue 48.5b / 47.6b) |
| TATA: -0.07 (NI 7.28b - CFO 13.3b) / TA 86.5b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 57.94 with a total of 5,317,350 shares traded. Over the past week, the price has changed by +3.82%, over one month by +3.74%, over three months by -1.47% and over the past year by +27.40%.
Current recommended Stop Loss: 56.00 (which is 3.3% or 1.3 ATR below the current price).
Bristol-Myers Squibb has received a consensus analysts rating of 3.48. Therefore, it is recommended to hold BMY.
- StrongBuy: 6
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 63 | 8.7% |
P/E Trailing = 16.2829
P/E Forward = 9.2166
P/S = 2.4484
P/B = 5.9152
P/EG = 1.5102
Revenue TTM = 48.5b USD
EBIT TTM = 10.5b USD
EBITDA TTM = 13.7b USD
Long Term Debt = 42.2b USD (from longTermDebt, last quarter)
Short Term Debt = 2.31b USD (from shortTermDebt, last quarter)
Debt = 46.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.97b
Net Debt = 35.9b USD (calculated: Debt 46.4b - CCE 10.5b)
Enterprise Value = 155b USD (119b + Debt 46.4b - CCE 10.5b)
Interest Coverage Ratio = 7.33 (Ebit TTM 10.5b / Interest Expense TTM 1.43b)
EV/FCF = 12.99x (Enterprise Value 155b / FCF TTM 11.9b)
FCF Yield = 7.70% (FCF TTM 11.9b / Enterprise Value 155b)
FCF Margin = 24.56% (FCF TTM 11.9b / Revenue TTM 48.5b)
Net Margin = 15.01% (Net Income TTM 7.28b / Revenue TTM 48.5b)
Gross Margin = 68.75% ((Revenue TTM 48.5b - Cost of Revenue TTM 15.2b) / Revenue TTM)
Gross Margin QoQ = 70.22% (prev 67.23%)
Tobins Q-Ratio = 1.79 (Enterprise Value 155b / Total Assets 86.5b)
Interest Expense / Debt = 3.07% (Interest Expense 1.43b / Debt 46.4b)
Taxrate = 24.22% (2.32b / 9.60b)
NOPAT = 7.93b (EBIT 10.5b * (1 - 24.22%))
Current Ratio = 1.42 (Total Current Assets 27.2b / Total Current Liabilities 19.2b)
Debt / Equity = 2.31 (Debt 46.4b / totalStockholderEquity, last quarter 20.1b)
Debt / EBITDA = 2.61 (Net Debt 35.9b / EBITDA 13.7b)
Debt / FCF = 3.02 (Net Debt 35.9b / FCF TTM 11.9b)
Total Stockholder Equity = 18.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.13% (Net Income 7.28b / Total Assets 86.5b)
RoE = 39.05% (Net Income TTM 7.28b / Total Stockholder Equity 18.6b)
RoCE = 17.21% (EBIT 10.5b / Capital Employed (Equity 18.6b + L.T.Debt 42.2b))
RoIC = 11.80% (NOPAT 7.93b / Invested Capital 67.2b)
WACC = 5.53% (E(119b)/V(165b) * Re(6.78%) + D(46.4b)/V(165b) * Rd(3.07%) * (1-Tc(0.24)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 0.23%
[DCF] Terminal Value 74.12% ; FCFF base≈12.4b ; Y1≈11.5b ; Y5≈10.4b
[DCF] Fair Price = 63.03 (EV 165b - Net Debt 35.9b = Equity 129b / Shares 2.04b; r=8.35% [WACC [floored]]; 5y FCF grow -9.00% → 2.50% )
EPS Correlation: 13.41 | EPS CAGR: 14.52% | SUE: 0.72 | # QB: 0
Revenue Correlation: 92.21 | Revenue CAGR: 3.10% | SUE: 2.58 | # QB: 10
EPS current Quarter (2026-06-30): EPS=1.61 | Chg30d=-0.13% | Revisions=-50% | Analysts=21
EPS next Quarter (2026-09-30): EPS=1.60 | Chg30d=-0.12% | Revisions=+0% | Analysts=21
EPS current Year (2026-12-31): EPS=6.31 | Chg30d=+0.01% | Revisions=+50% | GrowthEPS=+2.6% | GrowthRev=-1.8%
EPS next Year (2027-12-31): EPS=6.19 | Chg30d=+0.28% | Revisions=+18% | GrowthEPS=-1.9% | GrowthRev=-2.3%
[Analyst] Revisions Ratio: +16% (up=13, down=9)